Whether the therapeutic gene delivered to Ashanti replaced the defective copy of the ADA gene at the time of the first successful trial of gene therapy. Introduction: The FDA approved the first human gene therapy trial in 1990. This therapy started with the treatment of a young girl named Ashanti De Silva. She has a heritable disorder called adenosine deaminase severe combined immunodeficiency (ADA-SCID). SCID is a hereditary disease that is a result of many genetic mutations, such as the abnormal development of B and T cells.

Question

Want to see the full answer?

Answer 1

Question

Chapter ST.5, Problem 6RQ

Summary Introduction

To determine: Whether the therapeutic gene delivered to Ashanti replaced the defective copy of the ADA gene at the time of the first successful trial of gene therapy.

Introduction: The FDA approved the first human gene therapy trial in 1990. This therapy started with the treatment of a young girl named Ashanti De Silva. She has a heritable disorder called adenosine deaminase severe combined immunodeficiency (ADA-SCID). SCID is a hereditary disease that is a result of many genetic mutations, such as the abnormal development of B and T cells.

Summary Introduction

To determine: The reason for choosing white blood cells as the targets for the therapeutic gene.

Introduction: ADA-SCID is a condition that is affecting nearly 1-9 out of every 1 million live births. Individuals suffering from SCID lack a normal immune system. They generally die from minor infections.

Expert Solution & Answer

Want to see the full answer?

Check out a sample textbook solution

See solution

Students have asked these similar questions

The following table is from Kumar et. al. Highly Selective Dopamine D3 Receptor (DR) Antagonists and Partial Agonists Based on Eticlopride and the D3R Crystal Structure: New Leads for Opioid Dependence Treatment. J. Med Chem 2016.

The following figure is from Caterina et al. The capsaicin receptor: a heat activated ion channel in the pain pathway. Nature, 1997. Black boxes indicate capsaicin, white circles indicate resinferatoxin. You are a chef in a fancy new science-themed restaurant. You have a recipe that calls for 1 teaspoon of resinferatoxin, but you feel uncomfortable serving foods with "toxins" in them. How much capsaicin could you substitute instead?

What protein is necessary for packaging acetylcholine into synaptic vesicles?

Answer 2

Question

Chapter ST.5, Problem 6RQ

Summary Introduction

To determine: Whether the therapeutic gene delivered to Ashanti replaced the defective copy of the ADA gene at the time of the first successful trial of gene therapy.

Introduction: The FDA approved the first human gene therapy trial in 1990. This therapy started with the treatment of a young girl named Ashanti De Silva. She has a heritable disorder called adenosine deaminase severe combined immunodeficiency (ADA-SCID). SCID is a hereditary disease that is a result of many genetic mutations, such as the abnormal development of B and T cells.

Summary Introduction

To determine: The reason for choosing white blood cells as the targets for the therapeutic gene.

Introduction: ADA-SCID is a condition that is affecting nearly 1-9 out of every 1 million live births. Individuals suffering from SCID lack a normal immune system. They generally die from minor infections.

Expert Solution & Answer

Want to see the full answer?

Check out a sample textbook solution

See solution

Answer 3

Question

Chapter ST.5, Problem 6RQ

Summary Introduction

To determine: Whether the therapeutic gene delivered to Ashanti replaced the defective copy of the ADA gene at the time of the first successful trial of gene therapy.

Introduction: The FDA approved the first human gene therapy trial in 1990. This therapy started with the treatment of a young girl named Ashanti De Silva. She has a heritable disorder called adenosine deaminase severe combined immunodeficiency (ADA-SCID). SCID is a hereditary disease that is a result of many genetic mutations, such as the abnormal development of B and T cells.

Summary Introduction

To determine: The reason for choosing white blood cells as the targets for the therapeutic gene.

Introduction: ADA-SCID is a condition that is affecting nearly 1-9 out of every 1 million live births. Individuals suffering from SCID lack a normal immune system. They generally die from minor infections.

Expert Solution & Answer

Want to see the full answer?

Check out a sample textbook solution

See solution

Answer 4

Question

Chapter ST.5, Problem 6RQ

Summary Introduction

To determine: Whether the therapeutic gene delivered to Ashanti replaced the defective copy of the ADA gene at the time of the first successful trial of gene therapy.

Introduction: The FDA approved the first human gene therapy trial in 1990. This therapy started with the treatment of a young girl named Ashanti De Silva. She has a heritable disorder called adenosine deaminase severe combined immunodeficiency (ADA-SCID). SCID is a hereditary disease that is a result of many genetic mutations, such as the abnormal development of B and T cells.

Summary Introduction

To determine: The reason for choosing white blood cells as the targets for the therapeutic gene.

Introduction: ADA-SCID is a condition that is affecting nearly 1-9 out of every 1 million live births. Individuals suffering from SCID lack a normal immune system. They generally die from minor infections.

Expert Solution & Answer

Want to see the full answer?

Check out a sample textbook solution

See solution

Answer 5

Chapter ST.5, Problem 6RQ

Summary Introduction

To determine: Whether the therapeutic gene delivered to Ashanti replaced the defective copy of the ADA gene at the time of the first successful trial of gene therapy.

Introduction: The FDA approved the first human gene therapy trial in 1990. This therapy started with the treatment of a young girl named Ashanti De Silva. She has a heritable disorder called adenosine deaminase severe combined immunodeficiency (ADA-SCID). SCID is a hereditary disease that is a result of many genetic mutations, such as the abnormal development of B and T cells.

Summary Introduction

To determine: The reason for choosing white blood cells as the targets for the therapeutic gene.

Introduction: ADA-SCID is a condition that is affecting nearly 1-9 out of every 1 million live births. Individuals suffering from SCID lack a normal immune system. They generally die from minor infections.

Answer 6

Chapter ST.5, Problem 6RQ

Summary Introduction

To determine: Whether the therapeutic gene delivered to Ashanti replaced the defective copy of the ADA gene at the time of the first successful trial of gene therapy.

Introduction: The FDA approved the first human gene therapy trial in 1990. This therapy started with the treatment of a young girl named Ashanti De Silva. She has a heritable disorder called adenosine deaminase severe combined immunodeficiency (ADA-SCID). SCID is a hereditary disease that is a result of many genetic mutations, such as the abnormal development of B and T cells.

Answer 7

Chapter ST.5, Problem 6RQ

Summary Introduction

To determine: Whether the therapeutic gene delivered to Ashanti replaced the defective copy of the ADA gene at the time of the first successful trial of gene therapy.

Introduction: The FDA approved the first human gene therapy trial in 1990. This therapy started with the treatment of a young girl named Ashanti De Silva. She has a heritable disorder called adenosine deaminase severe combined immunodeficiency (ADA-SCID). SCID is a hereditary disease that is a result of many genetic mutations, such as the abnormal development of B and T cells.

Answer 8

Summary Introduction

To determine: The reason for choosing white blood cells as the targets for the therapeutic gene.

Introduction: ADA-SCID is a condition that is affecting nearly 1-9 out of every 1 million live births. Individuals suffering from SCID lack a normal immune system. They generally die from minor infections.

Answer 9

Summary Introduction

To determine: The reason for choosing white blood cells as the targets for the therapeutic gene.

Introduction: ADA-SCID is a condition that is affecting nearly 1-9 out of every 1 million live births. Individuals suffering from SCID lack a normal immune system. They generally die from minor infections.

Answer 10

Expert Solution & Answer

Answer 11

Expert Solution & Answer

Answer 12

Want to see the full answer?

Check out a sample textbook solution

See solution

Answer 13

Ch. ST.1 - What is the difference between innate immunity and...Ch. ST.1 - What evidence demonstrates that CRISPR-Cas is an...Ch. ST.1 - Prob. 3RQ Ch. ST.1 - Why was the type II CRISPR-Cas9 system of S....Ch. ST.1 - Prob. 5RQ Ch. ST.1 - What is a single guide RNA, and what role does it...Ch. ST.1 - What is the difference between nonhomologous...Ch. ST.1 - Prob. 8RQ Ch. ST.1 - Prob. 9RQ Ch. ST.1 - Prob. 1DQ

Solution Summary: The author explains that the therapeutic gene delivered to Ashanti did not replace the defective copy of the ADA gene.

Concept explainers

Videos

Want to see the full answer?

Chapter ST Solutions